Calcium Antagonists and Anesthesia

  • J. G. Reves
Chapter
Part of the Developments in Critical Care Medicine and Anesthesiolgy book series (DCCA, volume 6)

Abstract

The purpose of this report is to update a previous, more detailed review of calcium entry blockers and the implications these drugs have on anesthesia practice.1 In our previous paper we did not include diltiazem which has recently been released and whose pharmacology has been reviewed by McAuley and Schroeder.2 A number of other excellent review articles pertinent to the subject have also appeared since our listing of pertinent papers.3–11

Keywords

Calcium Antagonist Halothane Anesthesia Mitral Valve Disease Severe Hypotension Inhalation Anesthetic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. 1.
    Reves JG, Kissin I, Lell WA, Tosone S: Calcium entry blockers: Uses and implications for the anesthesiologists. Anesthesiology 57:504–518, 1982PubMedCrossRefGoogle Scholar
  2. 2.
    McAuley BJ, Schroeder JS: The use of diltiazem hydrochloride in cardiovascular disorders. Pharmacotherapy 2:121–133, 1982PubMedGoogle Scholar
  3. 3.
    Braunwald E: Mechanism of action of calcium-channel-blocking agents. N Engl J Med 307:1618–1627, 1982PubMedCrossRefGoogle Scholar
  4. 4.
    Movsesian MA: Calcium physiology in smooth muscle. Prog Cardiovasc Dis 25:211–224, 1982PubMedCrossRefGoogle Scholar
  5. 5.
    White BC, Winegar CD, Wilson RF, Hoehner PJ, Trombley JH Jr: Possible role of calcium blockers in cerebral resuscitation: A review of the literature and synthesis for future studies. Crit Care Med 11:202–207, 1983PubMedCrossRefGoogle Scholar
  6. 6.
    Weiss GB: New Perspectives on Calcium Antagonists. Bethesda, American Physiological Society, 1981Google Scholar
  7. 7.
    McAllister RG Jr: Clinical pharmacokinetics of calcium channel antagonists. J Cardiovasc Pharmacol 4:S340–S345, 1982PubMedCrossRefGoogle Scholar
  8. 8.
    Covinsky JO, Hamburger SC: Slow channel blockers. South Med J 76:55–64, 1983PubMedCrossRefGoogle Scholar
  9. 9.
    Fleckenstein A: History of calcium antagonists. Circ Res 52(Part II):I–3–I–17, 1983Google Scholar
  10. 10.
    Triggle DJ, Swamy VC: Calcium antagonists: Some chemical-pharmacologic aspects. Circ Res 52(Part II):I–17–I–28, 1983Google Scholar
  11. 11.
    Klein W, Brandt D, Vrecko K, Harringer M: Role of calcium antagonists in the treatment of essential hypertension. Circ Res 52(Part II):I–174–I–181, 1983Google Scholar
  12. 12.
    Braunwald E: Introduction: Calcium channel blockers. Am J Cardiol 46:1045–1046, 1980PubMedCrossRefGoogle Scholar
  13. 13.
    Zimpfer M, Fitzal S, Tonczar L: Verapamil as a hypotensive agent during neuroleptanaesthesia. Br J Anaesth 53:885–889, 1981PubMedCrossRefGoogle Scholar
  14. 14.
    Kates RA, Kaplan JA, McKeown PP, Freniere S: The cardiovascular effects of verapamil administration during coronary artery bypass graft surgery. Anesthesiology 57:A1, 1982CrossRefGoogle Scholar
  15. 15.
    Kopman EA: Intravenous verapamil to relieve pulmonary congestion in patients with mitral valve disease. Anesthesiology 58:374–376, 1983PubMedCrossRefGoogle Scholar
  16. 16.
    Zaggy AP, Kates RA, Norfleet EA, Mueller RA, Heath KR: The comparative cardiovascular effects of verapamil, nifedipine, and diltiazem during halothane anesthesia. SCA Fifth Annual Meeting, San Diego, CA, April 1983, pp 95-96Google Scholar
  17. 17.
    Komai H, Rusy BF: Effect of halothane on rested-state and potentiated-state contractions in rabbit papillary muscle: Relationship to negative inotropic action. Anesth Analg 61:403–409, 1982PubMedCrossRefGoogle Scholar
  18. 18.
    Blanck TJ, Thompson M: Calcium transport by cardiac sarcoplasmic reticulum: Modulation of halothane action by substrate concentration and pH. Anesth Analg 60:390–394, 1981PubMedGoogle Scholar
  19. 19.
    Lynch C, Vogel S, Sperelakis N: Halothane depresses cardiac slow action potentials. Anesthesiology 49:407–413, 1978CrossRefGoogle Scholar
  20. 20.
    Altura BM, Altura BT, Carella A, et al: Vascular smooth muscle and general anesthetics. Fed Proc 39:1584–1591, 1980PubMedGoogle Scholar
  21. 21.
    Tosone SR, Reves JG, Kissin I, Smith LR, Fournier SE: Hemodynamic responses to nifedipine in halothane anesthetized dogs. Anesth Analg 62: 000–000, 1983 (in press)CrossRefGoogle Scholar
  22. 22.
    Springman SR, Redon D, Rusy BF: The effect of nifedipine on the circulation during morphine N2O and halothane anesthesia in dogs. Anesth Analg 62:284–285, 1983Google Scholar
  23. 23.
    Kapur PA, Flacke WE: Epinephrine-induced arrhythmias and cardiovascular function after verapamil during halothane anesthesia in the dog. Anesthesiology 55:218–225, 1981PubMedCrossRefGoogle Scholar
  24. 24.
    Norfleet EA, Heath KR, Kopp VJ, Sprague DH, Corke BC: Verapamil — different cardiovascular responses during N2O analgesia and halothane anesthesia. Anesthesiology 57:A75, 1982CrossRefGoogle Scholar
  25. 25.
    Hantler CB, Clifford BD, Kroll DA, Knight PR: Verapamil does have prolonged interactions with halothane. Anesthesiology 57:A2, 1982CrossRefGoogle Scholar
  26. 26.
    Kapur PA, Flacke WE: Lack of correlation of verapamil plasma level with cumulative protective effects against halothane — epinephrine ventricular arrhythmias. J Cardiovasc Pharmacol 4:652–657, 1982PubMedCrossRefGoogle Scholar
  27. 27.
    Lawson NW, Kraynack BJ, Gintautas J: Neuromuscular and electrocardiographic responses to verapamil in dogs. Anesth Analg 62:50–54, 1983PubMedGoogle Scholar
  28. 28.
    Schick EC Jr, Liang C, Heupler FA Jr, et al: Randomized withdrawal from nifedipine: Placebo-controlled study in patients with coronary artery spasm. Am Heart J 104:690–697, 1982PubMedCrossRefGoogle Scholar
  29. 29.
    Freis ES, Lappas DG: Chronic administration of calcium entry blockers and the cardiovascular responses to high doses of fentanyl in man. Anesthesiology 57:A295, 1982CrossRefGoogle Scholar
  30. 30.
    Physicians’ Desk Reference, 37th Edition. Oradell, Medical Economics Company Inc., 1983, p 1580Google Scholar
  31. 31.
    Reves JG, Barker S, Smith LR: Significance of nifedipine plasma levels and hemodynamic changes during anesthesia induction. (Abstract) Anesthesiology (in press)Google Scholar
  32. 32.
    Marshall AG, Kissin I, Reves JG, Bradley EL Jr, Blackstone EH: Interaction between negative inotropic effects of halothane and nifedipine in the isolated rat heart. J Cardiovasc Pharmacol (in press)Google Scholar
  33. 33.
    Bikhazi GB, Leung I, Foldes FF: Interaction of neuromuscular blocking agents with calcium channel blockers. Anesthesiology 57:A268, 1982CrossRefGoogle Scholar
  34. 34.
    Maze M, Mason DM: Verapamil decreases the MAC for halothane in dogs. Anesth Analg 62:274, 1983Google Scholar
  35. 35.
    Kraynack BJ, Lawson NW, Gintautas J: Verapamil reduces indirect muscle twitch amplitude and potentiates pancuronium in vitro. Anesthesiology 57:A265, 1982CrossRefGoogle Scholar
  36. 36.
    Durant NN, Nguyen N, Briscoe JR, Katz RL: Potentiation of pancuronium and succinylcholine by verapamil. Anesthesiology 57:A267, 1982CrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1984

Authors and Affiliations

  • J. G. Reves

There are no affiliations available

Personalised recommendations